SAN FRANCISCO — It is important for ophthalmologists to understand FDA indications and develop a proper practice implementation strategy for new retinal drugs entering the market, according to a speaker here.
“In terms of reimbursement, we know that there are many challenges. The challenges for procedure reimbursement are that these are usually determined by CMS with [RVS Update Committee, RUC] input, and you have reevaluations by CMS, CPT or RUC-initiated [review of codes],” Ankoor R. Shah, MD, said at Retina Subspecialty Day at the American Academy of Ophthalmology meeting.